The IPPS is an independent and time-limited entity established to support the delivery of the #100DaysMission for diagnostics, therapeutics and vaccines 🧪💊💉
2/ Working through coalition - namely of therapeutics and diagnostics. All stakeholders need to come together - multisectoral partnership across govt industry CSO research and technical agencies.
Thank you for following along with today's event as part of @Devex Impact House @ #UNGA81, and thank you to our host @rumbiechakamba_ .
You can sign up to receive a recording of the event via Devex here: dvx.cm/bgxtab#100DaysMission
Anderson continues: ''Our preparation is about building the pipeline for MCMs. Companies do that mostly through partnership. One key thing is to find ways to capitalise investment and focus it on strengthening the antiviral pipeline''
@IFPMA#100DaysMission#UNGA81
Sowah continues: ''We also launched a Biological Security Strategy which complements the PPR strategy. We also have a cross-govt Board on 100DM. The 100 day goal can’t sit separately from national efforts on surveillance and manufacturing efforts”
#100DaysMission#UNGA81
Dr Priscila Ferraz Soares @fiocruz highlights: ''Brazil has launched new industrial policy focused on reducing external dependence, increasing mass production & new legislation on the health complex as a national asset for health security & innovation.''
#100DaysMission#UNGA81
@MedsPatentPool's Charles Gore comments: ''We need to have licenses in place and then triggered before a pandemic. Trying to put things in place interpandemic times to move as quickly as possible''
#100DaysMission#UNGA81
@DNDI's Rachel Cohen: ''This is a fragile moment - we know the geopolitical reality is devastating funding cuts. We have hope at @DNDi on research into antivirals - there’s an enormous appetite for collective and multisectoral action.''
#100DaysMission#UNGA81
@CEPIvaccines' @DrRHatchett on progress: ''#100DaysMission is an aspiration, but BDBV a perfect case to tell us how we’ve progressed towards it. We’re almost at Phase 1 trials. This is an example of Disease X in practice. 100DM is a multi year investment to get there.''
#UNGA81
.@DNDi's Rachel Cohen highlights a key gap: ''As set out by WHO & Africa CDC in The Lancet, although we have the beginnings of an ecosystem for vaccines, we have no ecosystem for therapeutics or for diagnostics''
#UNGA81